AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9088581 — intervention group
Group type: COMPARATOR
Intervention: Combined administration of sotalol and MAH
Number of subjects: 6
Study 1441789 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg recombinant human SOD (rh-SOD) administered intravenously 10-20 minutes prior to reperfusion
Number of subjects: 280
Study 1441789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study 3510232 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol hydrochloride
Number of subjects: 3837
Study 3510232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3837
Study 31295334 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled human malaria infection with P. falciparum sporozoites (Sanaria PfSPZ Challenge)
Number of subjects: 20
Study 28150972 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition - training to approach alternative activities and avoid smoking-related targets
Number of subjects: 0
Study 28150972 — intervention group
Group type: COMPARATOR
Intervention: Control condition - equal pushing and pulling of smoking and alternative activity-related targets
Number of subjects: 0
Study 26403133 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-coated Vicryl Plus
Number of subjects: 17
Study 26403133 — intervention group
Group type: COMPARATOR
Intervention: Vicryl (uncoated)
Number of subjects: 17
Study 23651789 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diacerein 1%
Number of subjects: 5
Study 23651789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 22185067 — intervention group
Group type: EXPERIMENTAL
Intervention: Stride Rite athletic shoes
Number of subjects: 12
Study 22185067 — intervention group
Group type: COMPARATOR
Intervention: flip flop sandals
Number of subjects: 12
Study 19244158 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (alloHSCT) with sibling donor (sib)
Number of subjects: 267
Study 19244158 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (alloHSCT) with matched unrelated donor (MUD)
Number of subjects: 267
Study 19244158 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 267
Study 19244158 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (alloHSCT)
Number of subjects: 267
Study 19244158 — intervention group
Group type: COMPARATOR
Intervention: Matched sibling donor availability
Number of subjects: 267
Study 17947606 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH + parenteral nutrition (PN)
Number of subjects: 24
Study 17947606 — intervention group
Group type: COMPARATOR
Intervention: parenteral nutrition (PN)
Number of subjects: 24
Study 15036719 — intervention group
Group type: EXPERIMENTAL
Intervention: 100mg methylprednisolone + 3mg granisetron
Number of subjects: 64
Study 15036719 — intervention group
Group type: EXPERIMENTAL
Intervention: 200mg methylprednisolone + 3mg granisetron
Number of subjects: 64
Study 14723439 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength-focused pre-intake form
Number of subjects: 88
Study 14723439 — intervention group
Group type: COMPARATOR
Intervention: Problem-focused pre-intake form
Number of subjects: 88
Study 9434647 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary dietary intervention over 3 years, teaching a diet low in total fat, saturated fat, and cholesterol, and high in polyunsaturated fat.
Number of subjects: 334
Study 9434647 — intervention group
Group type: COMPARATOR
Intervention: Usual-care (control) group, no specific intervention mentioned.
Number of subjects: 334
Study 7801186 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of low back pain literature
Number of subjects: 0
Study 7801186 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis
Number of subjects: 0
Study 7801186 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analytic methods
Number of subjects: 0
Study 3122554 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-based food supplement
Number of subjects: 12
Study 3122554 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-based food supplement plus breakfast meal
Number of subjects: 12
Study 3122554 — intervention group
Group type: COMPARATOR
Intervention: Lactose solution (control)
Number of subjects: 12
Study 4596406 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim sulfamethoxazole
Number of subjects: 39
Study 4596406 — intervention group
Group type: COMPARATOR
Intervention: Sulfamethoxazole alone
Number of subjects: 39
Study 31181140 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlapping (O) border
Number of subjects: 15
Study 31181140 — intervention group
Group type: EXPERIMENTAL
Intervention: Approximating (A) border
Number of subjects: 15
Study 28375640 — intervention group
Group type: EXPERIMENTAL
Intervention: Coriolus versicolor (CV)
Number of subjects: 15
Study 28375640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 26790206 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at single point (Bailao - EX-HN 15)
Number of subjects: 49
Study 26790206 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at multiple points (Bailao - EX-HN 15 and Hegu - LI 4)
Number of subjects: 49
Study 26790206 — intervention group
Group type: COMPARATOR
Intervention: Control group (19 healthy people)
Number of subjects: 49
Study 23662822 — intervention group
Group type: EXPERIMENTAL
Intervention: Global brain atrophy
Number of subjects: 97
Study 23662822 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age, male sex, and systemic inflammatory response syndrome (SIRS)
Number of subjects: 97
Study 23662822 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain atrophy
Number of subjects: 97
Study 20196640 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) - estradiol and progestogen
Number of subjects: 75
Study 20196640 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) with tamoxifen
Number of subjects: 75
Study 20196640 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 75
Study 19904267 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (900 mg m(‐2) over 30 min), oxaliplatin (65 mg m(‐2)), and 5‐FU (1500 mg m(‐2) over 24 h) on days 1 and 8 of a 21‐day cycle
Number of subjects: 72
Study 19904267 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine, oxaliplatin, and 5‐FU chemotherapy
Number of subjects: 72
Study 16761242 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/timolol 0.5% ophthalmic solution in the morning
Number of subjects: 92
Study 16761242 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/timolol 0.5% ophthalmic solution in the evening
Number of subjects: 92
Study 15006586 — intervention group
Group type: EXPERIMENTAL
Intervention: Care suggestions with symptom data
Number of subjects: 720
Study 15006586 — intervention group
Group type: COMPARATOR
Intervention: Care suggestions without symptom data (Control)
Number of subjects: 720
Study 11430537 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.4-0.8 mg/h over 24 h
Number of subjects: 30
Study 11430537 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (crossover after 24 h)
Number of subjects: 30
Study 11430537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8968883 — intervention group
Group type: EXPERIMENTAL
Intervention: Adeno-associated virus (AAV) detection in genital swab specimens from women suspected of having HSV infection
Number of subjects: 61
Study 8968883 — intervention group
Group type: COMPARATOR
Intervention: Control group (other clinical samples)
Number of subjects: 61
Study 8122736 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic solution at body temperature (37 +/- 1 degrees C)
Number of subjects: 40
Study 8122736 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthetic solution at room temperature (22 +/- 1 degrees C)
Number of subjects: 40
Study 3422548 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine therapy
Number of subjects: 15
Study 28005403 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit Reversal Training (HRT)
Number of subjects: 40
Study 28005403 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 40
Study 26271928 — intervention group
Group type: EXPERIMENTAL
Intervention: Family@play intervention
Number of subjects: 22
Study 26271928 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 24129396 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term intensive insulin therapy (IIT) consisting of basal insulin detemir and premeal insulin aspart for 4 weeks
Number of subjects: 63
Study 24129396 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term intensive insulin therapy (IIT)
Number of subjects: 63
Study 21406010 — intervention group
Group type: EXPERIMENTAL
Intervention: Chat line intervention for adolescents with type 1 diabetes
Number of subjects: 193
Study 21406010 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-participants)
Number of subjects: 193
Study 21406010 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between chat line participants and control group
Number of subjects: 193
Study 18715246 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate Cancer Prevention Trial (PCPT) risk calculator
Number of subjects: 0
Study 18715246 — intervention group
Group type: EXPERIMENTAL
Intervention: European Randomized Study of Screening for Prostate Cancer (ERSPC) risk calculator
Number of subjects: 0
Study 18715246 — intervention group
Group type: EXPERIMENTAL
Intervention: TRUS and prostate volume
Number of subjects: 0
Study 18715246 — intervention group
Group type: COMPARATOR
Intervention: Risk calculators comparison
Number of subjects: 0
Study 18605232 — intervention group
Group type: EXPERIMENTAL
Intervention: Daonil (10 mg glyburide)
Number of subjects: 24
Study 18605232 — intervention group
Group type: EXPERIMENTAL
Intervention: Gen-Glybe (10 mg glyburide)
Number of subjects: 24
Study 15360941 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted instruction (CAI) using cyberPatient (CP)
Number of subjects: 59
Study 15360941 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of textbook and CAI (CP)
Number of subjects: 59
Study 15360941 — intervention group
Group type: COMPARATOR
Intervention: Textbook for self-instruction
Number of subjects: 59
Study 15360941 — intervention group
Group type: COMPARATOR
Intervention: No learning (Group‐4)
Number of subjects: 59
Study 11320358 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/d atorvastatin
Number of subjects: 600
Study 11320358 — intervention group
Group type: COMPARATOR
Intervention: 40 mg/d pravastatin
Number of subjects: 600
Study 9227718 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast 337.5 mg twice daily
Number of subjects: 0
Study 9227718 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast 225 mg twice daily
Number of subjects: 0
Study 9227718 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast (both doses)
Number of subjects: 0
Study 9227718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8424425 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg bid
Number of subjects: 629
Study 8424425 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg tid
Number of subjects: 629
Study 8424425 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg qid
Number of subjects: 629
Study 8424425 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg hs
Number of subjects: 629
Study 3317345 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant yeast-derived hepatitis B vaccine (2.5, 5, 10, or 20 micrograms)
Number of subjects: 220
Study 3317345 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant yeast-derived hepatitis B vaccine (20 micrograms booster)
Number of subjects: 220
Study 3317345 — intervention group
Group type: COMPARATOR
Intervention: Plasma-derived hepatitis B vaccine (20 micrograms)
Number of subjects: 220
Study 31888741 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based body psychotherapy (BPT) with smartphone-triggered bodily intervention for 5 weeks, 6 days a week.
Number of subjects: 88
Study 31888741 — intervention group
Group type: COMPARATOR
Intervention: Group-based body psychotherapy (BPT) with smartphone-triggered control intervention for 5 weeks, 6 days a week.
Number of subjects: 88
Study 28846481 — intervention group
Group type: EXPERIMENTAL
Intervention: HA 0.15% and DQS 3% (Group 1)
Number of subjects: 0
Study 28846481 — intervention group
Group type: EXPERIMENTAL
Intervention: HA and Liposic EDO Gel (Group 2)
Number of subjects: 0
Study 28846481 — intervention group
Group type: EXPERIMENTAL
Intervention: HA, DQS, and Liposic EDO Gel (Group 3)
Number of subjects: 0
Study 25533398 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitors of histone deacetylases (HDACi)
Number of subjects: 100
Study 25533398 — intervention group
Group type: COMPARATOR
Intervention: CMV promoter
Number of subjects: 100
Study 25533398 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous expression cassettes targeted into two chromosomal sites using RMCE
Number of subjects: 100
Study 25533398 — intervention group
Group type: COMPARATOR
Intervention: Unrelated promoter
Number of subjects: 100
Study 25623561 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate anticoagulation
Number of subjects: 63
Study 25623561 — intervention group
Group type: COMPARATOR
Intervention: Heparin anticoagulation
Number of subjects: 63
Study 22139545 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Fructus bruceae oil (20 mL, 3 times per day for 12 weeks) combined with radiotherapy (60‐65 Gy, 6‐7 weeks)
Number of subjects: 80
Study 22139545 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 80
Study 19469786 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE₁‐EE (maximum 1000 μg) applied transdermally using an adhesive foil patch
Number of subjects: 34
Study 19469786 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 μg PGE₁‐EE)
Number of subjects: 34
Study 19469786 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE₁‐EE
Number of subjects: 34
Study 28095541 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser treatment
Number of subjects: 25
Study 28095541 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 ablative fractional resurfacing
Number of subjects: 25
Study 28095541 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with pulsed dye laser and CO2 ablative fractional resurfacing
Number of subjects: 25
Study 28095541 — intervention group
Group type: COMPARATOR
Intervention: CO2 ablative fractional resurfacing on the same day of surgery
Number of subjects: 25
Study 15478785 — intervention group
Group type: EXPERIMENTAL
Intervention: Trager treatment group
Number of subjects: 33
Study 15478785 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 33
Study 15478785 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 33
Study 11875895 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment in a rehabilitation centre in Tenerife for four weeks
Number of subjects: 88
Study 11875895 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment in two similar centres in Norway for four weeks
Number of subjects: 88
Study 11875895 — intervention group
Group type: COMPARATOR
Intervention: Ordinary health care programme (Control group)
Number of subjects: 88
Study 9558553 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralized freeze‐dried bone allograft with titanium-reinforced expanded polytetrafluoroethylene membranes in Group A
Number of subjects: 20
Study 9558553 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone chips with titanium-reinforced expanded polytetrafluoroethylene membranes in Group B
Number of subjects: 20
Study 8179148 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid priming solution
Number of subjects: 19
Study 8179148 — intervention group
Group type: COMPARATOR
Intervention: Colloid priming solution
Number of subjects: 19
Study 3117566 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of triglyceride emulsions (LCT; MCT/LCT)
Number of subjects: 0
Study 31087175 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile device app for postoperative education and self-assessment of recovery
Number of subjects: 97
Study 31087175 — intervention group
Group type: COMPARATOR
Intervention: Standard written education (control)
Number of subjects: 97
Study 30813926 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored 12-week strength and balance Exergame programme
Number of subjects: 106
Study 30813926 — intervention group
Group type: COMPARATOR
Intervention: Standard care (physiotherapy advice and leaflet)
Number of subjects: 106
Study 29273467 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint oil capsules (Colpermin)
Number of subjects: 80
Study 29273467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 25668012 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 13339
Study 25668012 — intervention group
Group type: COMPARATOR
Intervention: Mammography
Number of subjects: 13339
Study 25668012 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (Ultrasound + Mammography)
Number of subjects: 13339
Study 24064780 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental module for workers' health surveillance, including screening for work functioning impairments and mental health complaints.
Number of subjects: 0
Study 24064780 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 21333457 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive rearing system (Churra breed)
Number of subjects: 24
Study 21333457 — intervention group
Group type: COMPARATOR
Intervention: Intensive rearing system
Number of subjects: 24
Study 21333457 — intervention group
Group type: EXPERIMENTAL
Intervention: Churra breed
Number of subjects: 24
Study 21333457 — intervention group
Group type: EXPERIMENTAL
Intervention: Castellana breed
Number of subjects: 24
Study 19342295 — intervention group
Group type: EXPERIMENTAL
Intervention: 400mg modafinil
Number of subjects: 15
Study 19342295 — intervention group
Group type: EXPERIMENTAL
Intervention: modafinil
Number of subjects: 15
Study 19342295 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study 16965866 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy (55 Gy/20 fractions/4 weeks)
Number of subjects: 217
Study 16965866 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiation therapy (64 Gy/32 fractions/6.5 weeks)
Number of subjects: 217
Study 16965866 — intervention group
Group type: EXPERIMENTAL
Intervention: Both hypofractionated and conventional schedules
Number of subjects: 217
Study 16965866 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy
Number of subjects: 217
Study 16965866 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiation therapy
Number of subjects: 217
Study 14756266 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab 1 mg/kg
Number of subjects: 75
Study 14756266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 10777469 — intervention group
Group type: EXPERIMENTAL
Intervention: New chemotherapeutic agents (paclitaxel, docetaxel, vinorelbine, gemcitabine, irinotecan)
Number of subjects: 0
Study 10777469 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy regimens
Number of subjects: 0
Study 10777469 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined-modality programs
Number of subjects: 0
Study 10777469 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and cisplatin-based combination regimens
Number of subjects: 0
Study 8959593 — intervention group
Group type: EXPERIMENTAL
Intervention: STARS program (brief nurse consultations)
Number of subjects: 138
Study 8959593 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 138
Study 1313340 — intervention group
Group type: EXPERIMENTAL
Intervention: Fraxiparine subcutaneously 400 anti‐Xa Institute Choay units/kg
Number of subjects: 101
Study 1313340 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin by continuous intravenous infusion
Number of subjects: 101
Study 1313340 — intervention group
Group type: EXPERIMENTAL
Intervention: Fraxiparine subcutaneously 600 anti‐Xa Institute Choay units/kg
Number of subjects: 101
Study 1313340 — intervention group
Group type: EXPERIMENTAL
Intervention: Fraxiparine subcutaneously 900 anti‐Xa Institute Choay units/kg
Number of subjects: 101
Study 3862405 — intervention group
Group type: EXPERIMENTAL
Intervention: Birthing chair (upright position)
Number of subjects: 56
Study 3862405 — intervention group
Group type: COMPARATOR
Intervention: Bed (recumbent position)
Number of subjects: 56
Study 30843866 — intervention group
Group type: EXPERIMENTAL
Intervention: Blog intervention disseminated by mommy bloggers
Number of subjects: 798
Study 29152672 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosimilar filgrastim
Number of subjects: 98
Study 29152672 — intervention group
Group type: COMPARATOR
Intervention: Original G-CSFs (lenograstim and pegfilgrastim)
Number of subjects: 98
Study 29152672 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim
Number of subjects: 98
Study 27381263 — intervention group
Group type: EXPERIMENTAL
Intervention: SheathLess Eaucath GC (Asahi Intecc, Aichi, Japan)
Number of subjects: 233
Study 27381263 — intervention group
Group type: COMPARATOR
Intervention: Standard GC (Medtronic Launcher; Minneapolis, MN)
Number of subjects: 233
Study 23460503 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine (4 mg, with potential increase to 8 mg after 4 or 8 weeks)
Number of subjects: 654
Study 23460503 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine (double-blind treatment)
Number of subjects: 654
Study 23460503 — intervention group
Group type: COMPARATOR
Intervention: Placebo (double-blind treatment)
Number of subjects: 654
Study 22238574 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU+FT (Treatment as Usual plus Family Therapy)
Number of subjects: 60
Study 22238574 — intervention group
Group type: COMPARATOR
Intervention: TAU (Treatment as Usual)
Number of subjects: 60
Study 22238574 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU+FT
Number of subjects: 60